Teachers Advisors LLC increased its stake in Natera Inc (NASDAQ:NTRA) by 519.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 357,757 shares of the medical research company’s stock after acquiring an additional 300,047 shares during the quarter. Teachers Advisors LLC’s holdings in Natera were worth $8,565,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Pacer Advisors Inc. purchased a new stake in shares of Natera during the third quarter worth $106,000. Point72 Hong Kong Ltd purchased a new stake in shares of Natera during the third quarter worth $119,000. Quantbot Technologies LP purchased a new stake in shares of Natera during the third quarter worth $135,000. Meeder Asset Management Inc. grew its holdings in shares of Natera by 920.5% during the third quarter. Meeder Asset Management Inc. now owns 8,399 shares of the medical research company’s stock worth $200,000 after buying an additional 7,576 shares in the last quarter. Finally, United Services Automobile Association purchased a new stake in shares of Natera during the third quarter worth $214,000. 87.50% of the stock is owned by institutional investors and hedge funds.

NASDAQ NTRA traded up $0.01 during trading hours on Monday, reaching $14.76. The company had a trading volume of 14,216 shares, compared to its average volume of 514,781. Natera Inc has a 1-year low of $8.60 and a 1-year high of $29.62. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.44 and a quick ratio of 2.32. The stock has a market capitalization of $911.90 million, a P/E ratio of -6.15 and a beta of 1.79.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, November 8th. The medical research company reported ($0.49) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.03). Natera had a negative net margin of 58.00% and a negative return on equity of 2,569.52%. The company had revenue of $65.30 million during the quarter, compared to analyst estimates of $66.42 million. During the same period in the previous year, the company earned ($0.51) EPS. The company’s quarterly revenue was up 16.8% compared to the same quarter last year. As a group, analysts anticipate that Natera Inc will post -2.12 EPS for the current year.

A number of equities research analysts have recently issued reports on NTRA shares. Cowen reaffirmed a “buy” rating and set a $30.00 target price on shares of Natera in a report on Friday, November 9th. ValuEngine cut shares of Natera from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 9th. BidaskClub raised shares of Natera from a “strong sell” rating to a “sell” rating in a research report on Friday, December 7th. Finally, Zacks Investment Research cut shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, January 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Natera presently has an average rating of “Buy” and a consensus price target of $28.25.

WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/natera-inc-ntra-position-raised-by-teachers-advisors-llc/2813225.html.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: Stop Order

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.